Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Dyadic International Inc DYAI

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.


NDAQ:DYAI - Post by User

Post by AveragePennyon May 01, 2024 12:15pm
54 Views
Post# 36017571

Dyadic to Report First Quarter 2024 Financial Results

Dyadic to Report First Quarter 2024 Financial Results

JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024.

Conference Call Information:

Date: Tuesday, May 14, 2024

Time: 5:00 p.m. Eastern Time

Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560

Conference ID: 13743568

Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1650831&tp_key=0f89478e24. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.

If you have any questions that you would like to ask management during the Q&A session, please email hzosiak@dyadic.com prior to the conference call. 

 

https://www.globenewswire.com/news-release/2024/04/30/2872813/0/en/Dyadic-to-Report-First-Quarter-2024-Financial-Results-on-Tuesday-May-14-2024.html

<< Previous
Bullboard Posts
Next >>